Who are Articaine hydrochloride 2% solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ropivacaine + saline solution, Ropivacaine + dexamethasone, Ropivacaine Monohydrochloride, Triamcinolone + Lidocaine, TAP block with Bupivacaine at 0.25%, Ropivacaine with NaCl.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/articaine-hydrochloride-2-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Articaine hydrochloride 2% solution — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Articaine hydrochloride 2% solution (Articaine hydrochloride 2% solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic (amide type). Area: Anesthesia.

marketed Local anesthetic (amide type) Voltage-gated sodium channels Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Articaine hydrochloride 2% solution (Articaine hydrochloride 2% solution) — Helsinki University Central Hospital. Articaine hydrochloride is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Articaine hydrochloride 2% solution TARGET	Articaine hydrochloride 2% solution	Helsinki University Central Hospital	marketed	Local anesthetic (amide type)	Voltage-gated sodium channels
Ropivacaine + saline solution	Ropivacaine + saline solution	Federal University of Minas Gerais	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
Ropivacaine + dexamethasone	Ropivacaine + dexamethasone	Sahiwal medical college sahiwal	marketed	Local anesthetic with corticosteroid adjuvant	Voltage-gated sodium channels; glucocorticoid receptor
Ropivacaine Monohydrochloride	Ropivacaine Monohydrochloride	Clinique Saint-Jean, Bruxelles	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
Triamcinolone + Lidocaine	Triamcinolone + Lidocaine	MetroHealth Medical Center	marketed	Corticosteroid + Local anesthetic combination	Glucocorticoid receptor (triamcinolone); voltage-gated sodium channels (lidocaine)
TAP block with Bupivacaine at 0.25%	TAP block with Bupivacaine at 0.25%	Patricia Salazar Villegas	marketed	Local anesthetic	Voltage-gated sodium channels
Ropivacaine with NaCl	Ropivacaine with NaCl	Corewell Health East	marketed	Local anesthetic	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic (amide type) class)

Helsinki University Central Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Articaine hydrochloride 2% solution — Competitive Intelligence Brief. https://druglandscape.com/ci/articaine-hydrochloride-2-solution. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab